Companies SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS (SGMOQ): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Email me SANGAMO THERAPEUTICS, INC’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,392,272FY2023
- $2,457,450FY2024
CEO total pay was $2,457,450 in fiscal 2024, up from $2,392,272 in fiscal 2023.
FY2024: salary $716,366 · bonus $0 · stock awards $909,400 · option awards $0
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alexander Macrae | $716,366 | $0 | $909,400 | $0 | $825,254 | $0 | $6,430 | $2,457,450 |
| Chief Executive Officer | ||||||||
| Prathyusha Duraibabu | 483,960 | 0 | 323,974 | 0 | 371,681 | 0 | 6,430 | 1,186,045 |
| Chief Financial Officer | ||||||||
| Scott Willoughby | 457,800 | 0 | 323,974 | 0 | 351,590 | 0 | 6,430 | 1,139,794 |
| Chief Legal Officer & Corporate Secretary (5) | ||||||||
| Nathalie Dubois-Stringfellow | 453,600 | 0 | 323,974 | 0 | 348,365 | 0 | 6,430 | 1,132,369 |
| Chief Development Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Alexander Macrae | $2,457,450 | $2,392,272 | — | ↑ +65,178 |
| Prathyusha Duraibabu | 1,186,045 | 1,057,465 | — | ↑ +128,580 |
| Scott Willoughby | 1,139,794 | — | — | — |
| Nathalie Dubois-Stringfellow | 1,132,369 | 1,027,105 | — | ↑ +105,264 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
No outstanding equity awards are on file for this fiscal year.
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| H. Stewart ParkerIndependent · Nominating and Corporate Governance (Chair) | $106,250 | $14,190 | $19,885 | — | — | $140,325 |
| Robert F. CareyIndependent · Audit (Chair) | 75,000 | 14,190 | 19,885 | — | — | 109,075 |
| James R. MeyersIndependent · Audit · Compensation | 71,875 | 14,190 | 19,885 | — | — | 105,950 |
| Karen L. SmithIndependent · Compensation (Chair) | 68,750 | 14,190 | 19,885 | — | — | 102,825 |
| John H. MarkelsIndependent · Audit · Nominating and Corporate Governance | 68,750 | 14,190 | 19,885 | — | — | 102,825 |
| Kenneth J. HillanIndependent · Compensation | 59,375 | 14,190 | 19,885 | — | — | 93,450 |
| Courtney BeersIndependent · Compensation | 59,375 | 14,190 | 19,885 | — | — | 93,450 |
| Margaret A. HornIndependent · Nominating and Corporate Governance | 56,875 | 14,190 | 19,885 | — | — | 90,950 |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $566,250 |
| Equity awards (grant-date value) | $113,520 |
| All other compensation | $0 |
| Total cost of the board | $679,770 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names SANGAMO THERAPEUTICS as a peer
Companies that benchmark against SGMOQ
- Adaptimmune Therapeutics PLCADAPFY2024
- Avid Bioservices, Inc.CDMOFY2024
- CODEXIS, INC.CDXSFY2024
- Ginkgo Bioworks Holdings, Inc.DNAFY2025
- REGENXBIO Inc.RGNXFY2024
- RIGEL PHARMACEUTICALS INCRIGLFY2025
- SUTRO BIOPHARMA, INC.STROFY2025
- uniQure N.V.QUREFY2025
Each company listed discloses SGMOQ in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | SANGAMO THERAPEUTICS, INC | 2024 | Alexander Macrae | $716,366 | $909,400 | $0 | $825,254 | $2,457,450 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (15 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Alexander Macrae. DEF 14A, filed 2025-04-30. Section “Summary Compensation Table” · page 53. As printed: 2,457,450. View filing ↗
- Section 01, Prathyusha Duraibabu. DEF 14A, filed 2025-04-30. Section “Summary Compensation Table” · page 53. As printed: 1,186,045. View filing ↗
- Section 01, Scott Willoughby. DEF 14A, filed 2025-04-30. Section “Summary Compensation Table” · page 53. As printed: 1,139,794. View filing ↗
- Section 01, Nathalie Dubois-Stringfellow. DEF 14A, filed 2025-04-30. Section “Summary Compensation Table” · page 53. As printed: 1,132,369. View filing ↗
- Section 08, H. Stewart Parker. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 140,325. View filing ↗
- Section 08, Robert F. Carey. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 109,075. View filing ↗
- Section 08, James R. Meyers. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 105,950. View filing ↗
- Section 08, Karen L. Smith. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 102,825. View filing ↗
- Section 08, John H. Markels. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 102,825. View filing ↗
- Section 08, Kenneth J. Hillan. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 93,450. View filing ↗
- Section 08, Courtney Beers. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 93,450. View filing ↗
- Section 08, Margaret A. Horn. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 90,950. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 566,250 + equity 113,520 + all other 0 = 679,770, summed across the director compensation table rows.
- SANGAMO THERAPEUTICS, INC (subject), Section 10b CEO total. DEF 14A, filed 2025-04-30. CEO total compensation as printed in SANGAMO THERAPEUTICS, INC's own proxy. As printed: 2,457,450. View filing ↗